Stock GUTS FRACTYL HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fractyl Health, Inc.

Equities

GUTS

US35168W1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
4.44 USD -0.67% Intraday chart for Fractyl Health, Inc. +3.98% 0.00%
Jul. 01 Fractyl Health, Inc.(NasdaqGM:GUTS) added to Russell Small Cap Comp Value Index CI
Jul. 01 Fractyl Health, Inc.(NasdaqGM:GUTS) added to Russell Small Cap Completeness Index CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
FRACTYL HEALTH, INC. Stock Fractyl Health, Inc.
0.00% 213M - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
B+
ARGENX SE Stock argenx SE
+17.23% 25.91B
B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
B+
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.47% 15.6B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GUTS Stock
  4. Ratings Fractyl Health, Inc.